<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02566304</url>
  </required_header>
  <id_info>
    <org_study_id>15D.323</org_study_id>
    <secondary_id>2015-054</secondary_id>
    <secondary_id>NCI-2015-01506</secondary_id>
    <nct_id>NCT02566304</nct_id>
  </id_info>
  <brief_title>Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies</brief_title>
  <official_title>A Two Step Approach to Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies the use of reduced intensity chemotherapy and radiation therapy&#xD;
      before donor stem cell transplant in treating patients with hematologic malignancies. Giving&#xD;
      low doses of chemotherapy, such as cyclophosphamide and fludarabine phosphate, before a donor&#xD;
      stem cell transplant may help stop the growth of cancer cells. It may also stop the patient's&#xD;
      immune system from rejecting the donor's stem cells. The donated stem cells may replace the&#xD;
      patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor&#xD;
      effect). Reducing the intensity of the chemotherapy and radiation may also reduce the side&#xD;
      effects of the donor stem cell transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To demonstrate efficacy of this approach over the historical 2 step reduced intensity&#xD;
      conditioning (RIC) approaches in the &quot;vulnerable&quot; population defined as: patients with&#xD;
      hematopoietic cell transplant (HCT)-co-morbidity index (CI)/age scores &gt;= 2, but no more than&#xD;
      a score of 5 as based on the Sorror et al. data.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To compare the non-relapse mortality (NRM) and relapse related mortality (RRM) rates at 1&#xD;
      year for patients treated on this study to the that of patients undergoing haploidentical RIC&#xD;
      hematopoietic stem cell transplantation (HSCT) as reported in the literature and as observed&#xD;
      in the 2 step RIC trials.&#xD;
&#xD;
      II. To determine the incidence and severity of graft-versus-host disease (GVHD) in patients&#xD;
      undergoing treated on the Thomas Jefferson University (TJU) RIC 2 step approach.&#xD;
&#xD;
      III. To evaluate engraftment rates and lymphoid reconstitution in patients treated on the TJU&#xD;
      RIC 2 step approach.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      RIC: Patients receive fludarabine phosphate intravenously (IV) over 60 minutes on days -10 to&#xD;
      -8 and cyclophosphamide IV over 2 hours on days -3 and -2. Patients also undergo total body&#xD;
      irradiation (TBI) followed by a donor lymphocyte infusion (DLI) on day -6.&#xD;
&#xD;
      TRANSPLANT: Patients undergo cluster of differentiation (CD)34+ peripheral blood stem cell&#xD;
      transplant on day 0.&#xD;
&#xD;
      GVHD PROPHYLAXIS: Patients receive tacrolimus orally (PO) beginning day -1 with a taper&#xD;
      initiated on day 42 and mycophenolate mofetil IV twice daily (BID) on days -1 to 28 in the&#xD;
      absence of GVHD.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2015</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>At 1 year post HSCT</time_frame>
    <description>OS will be estimated using Kaplan-Meier curves. The 1-year OS rate and corresponding 95% confidence interval will be estimated from the Kaplan-Meier curve for the OS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse Related Mortality (RRM)</measure>
    <time_frame>At 1 year post HSCT</time_frame>
    <description>Will be reported descriptively. RRM may also be estimated using Kaplan Meier curves and/or cumulative incidence analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-Relapse Mortality (NRM)</measure>
    <time_frame>At 1 year post HSCT</time_frame>
    <description>Will be reported descriptively. NRM may also be estimated using Kaplan Meier curves and/or cumulative incidence analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of GVHD</measure>
    <time_frame>Up to 1 year post HSCT</time_frame>
    <description>Will be reported descriptively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment rates</measure>
    <time_frame>Up to 1 year post HSCT</time_frame>
    <description>Will be reported descriptively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphoid reconstitution</measure>
    <time_frame>Up to 1 year post HSCT</time_frame>
    <description>Lymphoid reconstitution will be evaluated monthly to every other month during the first year post HSCT and will be reported descriptively.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Myeloid Leukemia in Remission</condition>
  <condition>Aplastic Anemia</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Indolent Non-Hodgkin Lymphoma</condition>
  <condition>Malignant Neoplasm</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myeloproliferative Neoplasm</condition>
  <condition>Plasma Cell Myeloma</condition>
  <condition>Refractory Anemia</condition>
  <condition>Refractory Anemia With Excess Blasts</condition>
  <condition>Refractory Anemia With Ring Sideroblasts</condition>
  <condition>Refractory Cytopenia With Multilineage Dysplasia</condition>
  <condition>Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts</condition>
  <arm_group>
    <arm_group_label>RIC HSCT, GVHD prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RIC: Patients receive fludarabine phosphate IV on days -10 to -8 and cyclophosphamide IV on days -3 and -2. Patients also undergo TBI followed by a DLI on day -7.&#xD;
TRANSPLANT: Patients undergo CD34+ peripheral blood stem cell transplant on day 0.&#xD;
GVHD PROPHYLAXIS: Patients receive tacrolimus PO beginning day -1 with a taper initiated on day 42 and mycophenolate mofetil IV BID on days -1 to 28 in the absence of GVHD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>RIC HSCT, GVHD prophylaxis</arm_group_label>
    <other_name>Fludarabine phosphate</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>RIC HSCT, GVHD prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>T Cell-Depleted Donor Lymphocyte Infusion</intervention_name>
    <description>Undergo DLI</description>
    <arm_group_label>RIC HSCT, GVHD prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>RIC HSCT, GVHD prophylaxis</arm_group_label>
    <other_name>Endoxan</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Procytox</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>CP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo PBSC transplant</description>
    <arm_group_label>RIC HSCT, GVHD prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo PBSC transplant</description>
    <arm_group_label>RIC HSCT, GVHD prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given PO</description>
    <arm_group_label>RIC HSCT, GVHD prophylaxis</arm_group_label>
    <other_name>FK-506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Prograf</other_name>
    <other_name>Advograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>RIC HSCT, GVHD prophylaxis</arm_group_label>
    <other_name>Mycophenolic acid</other_name>
    <other_name>MMF</other_name>
    <other_name>CellCept</other_name>
    <other_name>Myfortic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients treated on this study will have:&#xD;
&#xD;
               1. Acute myeloid leukemia in morphologic CR not requiring treatment for their&#xD;
                  disease for 6 weeks&#xD;
&#xD;
               2. A history of AML with &lt; 20% residual blasts after induction therapy and&#xD;
                  persisting with &lt;20% blasts for at least 8 weeks without reinduction.&#xD;
&#xD;
               3. RA or RARS or isolated 5q- can proceed to transplant without any treatment&#xD;
&#xD;
               4. RAEB-1, RCMD+/-RS, or MDS NOS with stable disease for 6 months (as documented by&#xD;
                  serial bone marrow examinations) in the absence of any therapy but growth factors&#xD;
                  or transfusion support. Patients who require treatment to &quot;control their disease&quot;&#xD;
                  must show chemo-responsiveness&#xD;
&#xD;
               5. CMML or RAEB-2 must demonstrate chemo-responsiveness. Chemo-responsiveness is&#xD;
                  defined as a blast percentage decrease by at least 5 percentage points and there&#xD;
                  must be less than 20% blasts after treatment and at the time of transplant&#xD;
&#xD;
               6. Hodgkin or Indolent Non-Hodgkin's lymphoma&#xD;
&#xD;
               7. Myeloma with &lt; 5% plasma cells in the marrow&#xD;
&#xD;
               8. Myeloproliferative disorders&#xD;
&#xD;
               9. Aplastic Anemia&#xD;
&#xD;
              10. A hematological or oncological disease (not listed) in which allogeneic HSCT is&#xD;
                  thought to be beneficial, and the disease is chemoresponsive.&#xD;
&#xD;
              11. Patients without clear manifestation of their disease status in terms of stage&#xD;
                  and/or responsiveness should be discussed with the PI and enrollment analysis&#xD;
                  should be documented in the study records.&#xD;
&#xD;
          2. Patients must have a related donor who is HLA mismatched at 2, 3, or 4 antigens at the&#xD;
             HLA-A; B; C; DR loci in the GVHD direction. (Patients with related donors who are HLA&#xD;
             identical or are a 1-antigen mismatch may be treated on this therapeutic approach, but&#xD;
             will have their outcomes will not be part of the statistical aims of the study (see&#xD;
             Statistical Section). The HLA matched related category includes patients with a&#xD;
             syngeneic donor.&#xD;
&#xD;
          3. Patients must have had front line therapy for their disease.&#xD;
&#xD;
          4. Patients must adequate organ function:&#xD;
&#xD;
               1. LVEF (Left ventricular end diastolic function) of &gt;/=45%.&#xD;
&#xD;
               2. DLCO (Diffusing Capacity of the Lung for Carbon Monoxide ) ≥45% of predicted&#xD;
                  corrected for hemoglobin, FEV-1 (forced expiratory volume at 1 second ≥50% of&#xD;
                  predicted&#xD;
&#xD;
               3. Adequate liver function as defined by a serum bilirubin &lt;1.8, AST or ALT &lt; 2.5X&#xD;
                  upper limit of normal&#xD;
&#xD;
               4. Creatinine Clearance of ≥ 60 mL/min&#xD;
&#xD;
          5. HCT-CI/Age Score ≤ 5 points (Patients with greater than 5 points will be allowed for&#xD;
             trial with approval of the PI and the Co-PI or his designee. This is an adjustment to&#xD;
             account for healthy patients who meet the spirit of this protocol but have histories&#xD;
             that result in higher than HCT-CI 5 points. An example is a patient with a solid tumor&#xD;
             malignancy in their remote history (adds 3 points to HCT-CI total) where the treatment&#xD;
             for the malignancy occurred years to decades before and there has been complete&#xD;
             recovery of toxicities.&#xD;
&#xD;
          6. KPS≥ 90% patients older than 70 years, KPS≥ 80% patients younger than 70 years&#xD;
&#xD;
          7. Patients must be willing to use contraception if they have childbearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Performance status &lt; 90% in patients 70 years old or greater, &lt;80% in patients less&#xD;
             than age 70 years&#xD;
&#xD;
          2. HCT-CI/age Score &gt;5 points (Patients with greater than 5 points will be allowed for&#xD;
             trial with approval of the Principal Investigator and the Co-Principal Investigator or&#xD;
             his designee. This is an adjustment to account for healthy patients who meet the&#xD;
             spirit of this protocol but have histories that result in higher than HCT-CI 5 points.&#xD;
             An example is a patient with a solid tumor malignancy in their remote history (adds 3&#xD;
             points to HCT-CI total) where the treatment for the malignancy occurred years to&#xD;
             decades before and there has been complete recovery of toxicities.&#xD;
&#xD;
          3. A diagnosis of CMML, unless in morphologic CR&#xD;
&#xD;
          4. HIV positive&#xD;
&#xD;
          5. Active involvement of the central nervous system with malignancy&#xD;
&#xD;
          6. Inability to obtain informed consent from patient or surrogate&#xD;
&#xD;
          7. Pregnancy&#xD;
&#xD;
          8. Patients with life expectancy of &lt; 6 months for reasons other than their underlying&#xD;
             hematologic/oncologic disorder&#xD;
&#xD;
          9. Patients who have received alemtuzumab or antithymocyte globulin within 8 weeks of the&#xD;
             transplant admission. The absence of these therapies in the medical record will serve&#xD;
             as documentation that they were not given.&#xD;
&#xD;
         10. Patients with evidence of another malignancy, exclusive of a skin cancer that requires&#xD;
             only local treatment, should not be enrolled on this protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dolores Grosso, DNP, CRNP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neal Flomenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dolores Grosso, DNP, CRNP</last_name>
    <phone>215-955-8874</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dolores Grosso, DNP, CRNP</last_name>
      <phone>215-955-8874</phone>
    </contact>
    <investigator>
      <last_name>Dolores Grosso, DNP, CRNP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Neal Flomenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>S. Onder Alpdogan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Carabasi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joanne Filicko-O'Hara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margaret Kasner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Klumpp, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William O'Hara, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ubaldo Martinez Outschoorn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manish Sharma, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Wagner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Weiss, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.kimmelcancercenter.org/cancer-center.html</url>
    <description>Sidney Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center</description>
  </link>
  <link>
    <url>http://hospitals.jefferson.edu/</url>
    <description>Jefferson University Hospitals</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 30, 2015</study_first_submitted>
  <study_first_submitted_qc>September 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2015</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Anemia, Refractory</mesh_term>
    <mesh_term>Anemia, Refractory, with Excess of Blasts</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

